CD
Charles Duncan Cantor Fitzgerald Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Acadia Pharmaceuticals
ACAD
$4.28B
| $24.84 | $28 |
13%
upside
| Overweight |
27 Feb ‘25
6 months ago |
|
2
Jazz Pharmaceuticals
JAZZ
$7.88B
| $128.53 | $150 |
17%
upside
| Neutral |
26 Feb ‘25
6 months ago |
|
3
Axsome Therapeutics
AXSM
$6.45B
| $125.68 | $153 |
22%
upside
| Overweight |
19 Feb ‘25
6 months ago |
|
4
GH Research
GHRS
$838M
| $13.42 | $14 |
4%
upside
| Overweight |
13 Feb ‘25
6 months ago |
|
5
Harmony Biosciences
HRMY
$2.06B
| $34 | $58 |
71%
upside
| Overweight |
30 Oct ‘24
10 months ago |
|
6
Alkermes
ALKS
$4.7B
| $27.85 | $43 |
54%
upside
| Overweight |
25 Oct ‘24
10 months ago |
|
7
Neurocrine Biosciences
NBIX
$14.3B
| $144.17 | $155 |
8%
upside
| Overweight |
16 Sep ‘24
11 months ago |
|
8
Denali Therapeutics
DNLI
$2.27B
| $15.36 | $35 |
128%
upside
| Overweight |
9 Sep ‘24
1 year ago |
|
9
Vanda Pharmaceuticals
VNDA
$269M
| $4.51 | $13 |
188%
upside
| Overweight |
1 Aug ‘24
1 year ago |
|
10
Catalyst Pharmaceutical
CPRX
$2.46B
| $20 | $34 |
70%
upside
| Overweight |
22 Mar ‘24
1 year ago |
|
11
Crinetics Pharmaceuticals
CRNX
$3.31B
| $36.50 | $50 |
37%
upside
| Overweight |
24 Oct ‘23
1 year ago |
|
12
Solid Biosciences
SLDB
$399M
| $5 | $5 |
0%
upside
| Overweight |
22 Sep ‘23
1 year ago |
|
13
Lucid Diagnostics
LUCD
$125M
| $1.27 | $4 |
215%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
14
Xenon Pharmaceuticals
XENE
$2.94B
| $37.51 | $58 |
55%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
15
BioVie
BIVI
$13.6M
| $1.79 | $1,100 |
61,353%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
16
Clene
CLNN
$66.2M
| $6.60 | $80 |
1,112%
upside
| Overweight |
16 Aug ‘23
2 years ago |
|
|
CRDL
17
Cardiol Therapeutics
CRDL
$87.9M
| $1.03 | $3 |
191%
upside
| Overweight |
14 Aug ‘23
2 years ago |
|
18
Anavex Life Sciences
AVXL
$803M
| $10.26 | $11 |
7%
upside
| Neutral |
6 Dec ‘22
2 years ago |
|
19
Fennec Pharmaceuticals
FENC
$251M
| $9.22 | $12 |
30%
upside
| Overweight |
22 Nov ‘22
2 years ago |
|
20
Novavax
NVAX
$1.26B
| $7.96 | $168 |
2,011%
upside
| Overweight |
8 Jun ‘22
3 years ago |
|
21
Oramed Pharmaceuticals
ORMP
$94.3M
| $2.31 | $20 |
766%
upside
| Overweight |
18 Feb ‘22
3 years ago |
|
22
vTv Therapeutics
VTVT
$49.1M
| $18.77 | $200 |
966%
upside
| Overweight |
18 Feb ‘22
3 years ago |
|
|
NEUP
23
Neuphoria Therapeutics Inc. Common Stock
NEUP
$24.4M
| $15.10 | $52 |
244%
upside
| Overweight |
10 Jan ‘22
3 years ago |
|
24
Ovid Therapeutics
OVID
$88.2M
| $1.24 | $4 |
223%
upside
| Neutral |
20 Apr ‘21
4 years ago |
|
25
Cassava Sciences
SAVA
$103M
| $2.18 | $24 |
1,001%
upside
| Overweight |
23 Oct ‘20
4 years ago |
|